Hypopharyngeal carcinomas most frequently harbor alterations in TP53, CDKN2A, KMT2D, CCND1, and PIK3CA .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, TP53 Exon 7 Mutation, and TP53 Exon 5 Mutation are the most common alterations in hypopharyngeal carcinoma .
There are 4 clinical trials for hypopharyngeal carcinoma, of which 3 are open and 1 is completed or closed. Of the trials that contain hypopharyngeal carcinoma as an inclusion criterion, 1 is phase 1 (0 open), 2 are phase 2 (2 open), and 1 is phase 2/phase 3 (1 open).
Atezolizumab, cetuximab, and cisplatin are the most common interventions in hypopharyngeal carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.